The primary objective of our research program is to identify and therapeutically exploit genetic determinants of immune vulnerability in brain tumors. Despite the transformative impact of immunotherapy in several cancers, its benefit in glioblastoma (GBM)—the most aggressive primary brain tumor—has been minimal. We employ genome-wide CRISPR screening, integrated with cellular, molecular, and immunological approaches, to systematically investigate regulators of anti-tumor immunity. A major focus of our lab is on the Checkpoint Kinase 2 (CHEK2) pathway, a key mediator of DNA damage response with emerging relevance in tumor immunobiology. Ongoing studies explore the role of CHEK2 as a therapeutic vulnerability in both glioblastoma and meningioma, with the goal of advancing it toward clinical translation.